Additional Ph1 studies are ongoing that will assess the efficacy of VX-970 in combination with various DNA damaging chemotherapies in TP53 mutant patients or in disease with a high rate of TP53 mutation, e.g., triple-negative breast cancer with a basaloid histology. The gene discussed is TP53; the disease is triple-negative breast carcinoma.